ArticleFrontiers in neurology2025
Outpatient interface challenges for drug safety in Parkinson's disease patients: a questionnaire based cross-sectional study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Searching for a needle in a haystack-ambulatory research in Parkinson's disease in Germany.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a chronic and multifaceted disease with a variety of motor and non-motor symptoms. The safe symptomatic drug therapy of often multimorbid patients places enormous demands on the competence, communication and coordination of the treating physicians, particularly in the outpatient sector. Objectives: This study aimed to explore aspects of drug safety and interdisciplinary communication in the outpatient sector of PD patients. Methods: A semistructured questionnaire was designed addressing various aspects of drug safety in the outpatient setting. The questionnaire was sent to a total of 1,002 general practitioners (GP) and 1,005 neurologists (NEU). Results: One hundred and forty-seven NEU and eighty-four GP answered the questionnaire. Overall, NEU treated more PD patients, while GP cared for more geriatric PD patients, especially outside of the outpatient clinic (home visits, nursing homes). Regarding the execution of recommended laboratory or technical check-ups, as well as the prescription of new medications, neither a formal agreement nor structured communication existed. Merely the identification of potential drug-drug interactions (DDI) was regularly carried out by both professions. Conclusion: The inadequate interdisciplinary communication hampers therapy safety and consequently the safety of the vulnerable PD patient group. For this reason, standardized and comprehensive communication mechanisms are urgently needed. Solution approaches may include an individual protected digital health record or integrated treatment networks comprising all professionals participating in the management of PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.